Category: Technology Licenses
Created On: 2022-04-28
Record Count: 7
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 183244
This agreement is for the pharmaceutical industry, excluding oncology use.
IPSCIO Record ID: 28062
IPSCIO Record ID: 269086
The Licensor is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The pioneering research focuses on signaling pathways that are critical to disease mechanisms.
Adult chronic immune thrombocytopenic purpura (chronic ITP) is an autoimmune disorder in which patients produce antiplatelet autoantibodies and specialized white blood cells that destroy their blood platelets and, in some cases, damage their megakaryocytes (the cells that produce platelets in the bone marrow), causing a decrease in platelet production. This results in a low blood platelet count (thrombocytopenia) that may produce bruising or excessive bleeding.
IPSCIO Record ID: 7426
The development rights under the License Agreement are exclusive for the term of the Agreement with respect to RXDX-101 and RXDX-102 and also, as to the Licensor, are exclusive for a five-year period with respect to any product candidate with activity against the target proteins of RXDX-101 and RXDX-102, and include the right to grant subLicenses.
RXDX-102 is a tyrosine kinase inhibitor directed to the Trk family tyrosine kinase receptors, TrkA, TrkB and TrkC, which is currently in preclinical development for the treatment of multiple cancers. Tyrosine kinases are enzymes that transfer phosphate groups from adenosine triphosphate (ATP) to cellular proteins and can function as an on/off switch for cellular functions, including cancer signaling.
IPSCIO Record ID: 123666
Hypercholesterolemia, also called dyslipidemia, is the presence of high levels of cholesterol in the blood.
IPSCIO Record ID: 364268
The Licensee exercised the Topical BETi Option, granting Licensee a worldwide, exclusive license that is sublicensable through multiple tiers to exploit certain of Licensorâ€™s BETi compounds identified to be suitable for topical administration in all fields. The Licensee has the sole responsibility for development, regulatory, marketing and commercialization activities to be conducted for the licensed topical products.
The agreement relates to the discovery and development of proprietary Bromodomain and Extra-Terminal Domain inhibitors (â€œBET inhibitorâ€ or â€œBETiâ€) for the treatment of immunology and oncology conditions.
IPSCIO Record ID: 27879